-
Company Insights
New![]()
Innovation and Patenting activity of GC Biopharma Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of GC Biopharma Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Net Present Value Model: Gracell Biotechnologies Inc’s GC-012F
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-1109 in Anthrax
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GC-1109 in Anthrax Drug Details: GC-1109 is under development for the prevention of anthrax. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-101 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GC-101 in Melanoma Drug Details:GC-101 is under development for the treatment of gastrointestinal tumors, epidermolysis bullosa,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-3107A in Tuberculosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-3107A in Tuberculosis Drug Details: GC-3107 is under development for the prevention of tuberculosis....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-101 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GC-101 in Metastatic Melanoma Drug Details: GC-101 is under development for the treatment of gastrointestinal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-101 in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GC-101 in Breast Cancer Drug Details:GC-101 is under development for the treatment of gastrointestinal tumors, epidermolysis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-1118A in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GC-1118A in Gastric Cancer Drug Details: GC-1118A is under development for the treatment of gastric...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-197 in Lymphoblastic Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GC-197 in Lymphoblastic Lymphoma Drug Details:GC-197 is under development for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GC-101 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GC-101 in Cervical Cancer Drug Details:GC-101 is under development for the treatment of gastrointestinal tumors, epidermolysis...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.